GLP1R and cholangiocarcinoma: During 1,036,587 person-years of follow-up, cholangiocarcinoma occurred among 92 patients with use of GLP-1-receptor agonists (incidence rate, 26 per 100,000 patient-years) and among 157 patients with use of sulfonylureas (incidence rate, 23 per 100,000 patient-years).